Improving the selection and development of influenza vaccine viruses Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015
Improving the selection and development of influenza vaccine viruses Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015
复制标题
DOI：
10.1016/j.vaccine.2017.01.018
复制
发表时间：
2017-02-22
期刊：
影响因子：
5.5
通讯作者：
Zhang Wenqing
中科院分区：
文献类型：
--
作者：
Alan, Hampson;Ian, Barr;Zhang Wenqing
自2010年以来，世卫组织举行了一系列非正式磋商，探讨如何改进目前高度复杂和时间紧迫的流感疫苗病毒选择和开发过程。2015年11月，来自世界各地的专家们齐聚一堂，回顾了该领域的工作现状，讨论的主题包括加强流感监测活动，以增加候选疫苗病毒的可用性，并提高监测数据的范围、及时性和质量。还考虑了新的实验室检测方法的开发和潜在应用，以更好地表征候选疫苗病毒，针对流感病毒神经氨酸酶的抗体的潜在重要性，以及疫苗有效性研究的作用。会议还讨论了流感病毒下一代测序和全基因组测序的进展，沿着合成基因组学技术、进化分析和预测数学建模的相关发展，还讨论了2014年年中出现的抗原性变异甲型流感（H3 N2）病毒，该病毒未能及时纳入2014-15年北方疫苗。与会者普遍认识到，鉴于目前流感疫苗的开发和生产时间轴受到高度限制，在相关的世卫组织半年一次的流感疫苗组成会议之后很长一段时间，仍不可能纳入任何出现的变异病毒。会议还讨论了大流行性和广泛保护性疫苗的开发以及相关的监管和生产要求和限制。随着人们越来越认识到季节性流感造成的健康和经济负担、人畜共患流感病毒造成的持续威胁以及2014-15年北方季节性流感疫苗错配的重大影响，这次磋商提供了一个非常及时的机会来分享事态发展和交换意见。在所有领域，都重新强调并加强了制定具体和可衡量的行动，并确定负责执行这些行动的主要利益攸关方。(C)2017作者爱思唯尔有限公司出版
Since 2010 the WHO has held a series of informal consultations to explore ways of improving the currently highly complex and time-pressured influenza vaccine virus selection and development process. In November 2015 experts from around the world met to review the current status of efforts in this field.Discussion topics included strengthening influenza surveillance activities to increase the availability of candidate vaccine viruses and improve the extent, timeliness and quality of surveillance data. Consideration was also given to the development and potential application of newer laboratory assays to better characterize candidate vaccine viruses, the potential importance of antibodies directed against influenza virus neuraminidase, and the role of vaccine effectiveness studies. Advances in next generation sequencing and whole genome sequencing of influenza viruses were also discussed, along with associated developments in synthetic genomics technologies, evolutionary analysis and predictive mathematical modelling.Discussions were also held on the late emergence of an antigenic variant influenza A(H3N2) virus in mid-2014 that could not be incorporated in time into the 2014-15 northern hemisphere vaccine. There was broad recognition that given the current highly constrained influenza vaccine development and production timeline it would remain impossible to incorporate any variant virus which emerged significantly long after the relevant WHO biannual influenza vaccine composition meetings. Discussions were also held on the development of pandemic and broadly protective vaccines, and on associated regulatory and manufacturing requirements and constraints.With increasing awareness of the health and economic burdens caused by seasonal influenza, the everpresent threat posed by zoonotic influenza viruses, and the significant impact of the 2014-15 northern hemisphere seasonal influenza vaccine mismatch, this consultation provided a very timely opportunity to share developments and exchange views. In all areas, a renewed and strengthened emphasis was placed on developing concrete and measurable actions and identifying the key stakeholders responsible for their implementation. (C) 2017 The Authors. Published by Elsevier Ltd.